My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Expression of FOXP3, CD68 and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma is Predictive of outcome. J Clin Oncol (2013) 31(2):256-62. PMID: 23045593
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA (2009) 106(15):6250-5. PMID: 19332800
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 118(7):2427-37. PMID: 18551193
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood (2008) 112(2):394-7. PMID: 18434611
The research interest of my group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding:
Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings Seymour JF, Gribben JG, Davids MS et al. Blood (2020) 136(10) 37-38
Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia Bloehdorn J, Braun A, Jebaraj BMC et al. Blood (2020) 136(10) 12-13
Access to Affordable Orphan Medicines in Europe: An EHA Position Paper. Merlini G, Gribben J, Macintyre E et al. Hemasphere (2020) 4(2) e477
Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer Roy-Luzarraga M, Abdel-Fatah T, Reynolds LE et al. JAMA network open (2020) 3(7) e2019304
Fair Pricing of Innovative Medicines: An EHA Position Paper. Hagenbeek A, Gribben J, Jäger U et al. Hemasphere (2020) 4(2) e488
Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper. Jäger U, Kapitein P, Gribben J Hemasphere (2020) 4(2) e474
Subgroup analyses of patients aged >= 70 years in AUGMENT: Phase III randomized study of Lenalidomide plus rituximab (R-2) vs rituximab plus placebo (R-placebo) in patients with Relapsed/Refractory (R/R) indolent Non-Hodgkin Lymphoma (iNHL) La Rosee P, Graeven U, Leonard JP et al. ONCOLOGY RESEARCH AND TREATMENT (2020) 43(11) 68-68
Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD Ball J, Clear A, Aries J et al. Blood (2020) (1)
Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative Anthias C, Apperley J, Bloor A et al. Bone Marrow Transplantation (2020) 55(7) 1840-1843
Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells Wong PP, Muñoz-Félix JM, Hijazi M et al. Cell (2020) 181(7) 1346-1363.e21For additional publications, please click here
Group Leaders in the Centre
Dr Andrejs Braun, Dr Pedro Cutillas, Dr Jeff Davies, Dr Gabriella Ficz, Professor Jude Fitzgibbon, Dr Li Jia, Professor Kamil R. Kranc, Dr Sergey Krysov, Dr Rifca Le Dieu, Dr Kevin Rouault-Pierre, Dr John Riches, Dr Bela Wrench
Clinical Research Fellows
Dr Jennifer Edelmann, Dr Robin Sanderson, Dr Joseph Taylor, Dr Edward Truelove
I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.
In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.